Background: Mice with targeted disruption of the gene for the neuronal isoform of nitric oxide synthase (nNOS) display exaggerated aggression. Behavioral studies of mice with targeted gene deletions suffer from the criticism that the gene product is missing not only during the assessment period but also throughout development when critical processes, including activation of compensatory mechanisms, may be affected. To address this criticism, we have assessed aggressive behavior in mice treated with a specific pharmacological inhibitor of
INTRODUCTION
Nitric oxide (NO) is formed by several subtypes of nitric oxide synthase (NOS) associated with the different functions of NO throughout the body. Blood pressure is regulated by endothelial NOS (eNOS), macrophage function is modulated by inducible NOS (iNOS), while the neurotrans-mitter pool of NO is synthesized primarily by neuronal NOS (nNOS), though central nervous system neurons also may possess eNOS (1) . Efforts to understand the role of NO in brain function have been assisted by the availability of mice with targeted disruption of nNOS (nNOS-) (2) . These mice resist brain damage following middle cerebral artery occlusion (3) . nNOS-animals display distended stomachs with hypertrophied pyloric sphincters which is associated with disorders in gastrointestinal motility and reflects loss of nNOS in myenteric plexus neurons (2) .
Much of the behavior of nNOS-animals G. E. Demas et al. Nitric Oxide and Aggression 611 appears grossly normal with no defects observed in locomotor activity, breeding (4, 5) , long-term potentiation in the hippocampus (6) , long-term depression in the cerebellum (7) , and overall sensorimotor function (4) . However, male nNOS-animals display dramatic increases in aggressive behavior and excessive inappropriate sexual behavior (4) . Like most other gene knockout mice, nNOS -animals were created utilizing stem cells from 129SvEv animals injected into C57BL/6J mice, thus the knockout animals are a hybrid of two strains. It has been suggested that this mixture of strains could contribute to nNOS-behavioral abnormalities (8 (9) . In the present study we report that 7-NI administration evokes a substantial increase in aggressive behavior of male mice, resembling effects observed in nNOS-animals.
MATERIALS AND METHODS

Materials
The citrulline antiserum has been previously described (10 20 min with 0.5% NaBH4 and 0.2% Na2S205 in phosphate-buffered saline (PBS) (10 mM, pH 7.4/0.19 M NaCl), washed for 45 min at room temperature in PBS containing 0.2% Na2S205, blocked with 4% normal goat serum for 1 hr in the presence of 0.2% Triton X-100, and incubated overnight at 4°C with the primary antiserum diluted in PBS containing 2% goat serum and 0.1 % Triton X-100. The citrulline and nNOS antisera were used at 1:10,000 and 1:15,000 dilutions, respectively. Immunoreactivity was visualized with the Vectastain ABC Elite kit. Immunohistochemistry was routinely done in the presence of liquid-phase glutaraldehyde conjugates of L-arginine and L-glutamate to minimize any cross-reactivity to amino acids with similar structure to citrulline that occur in high concentrations in brain.
RESULTS
7-Nitroindazole Increases Aggressive Behavior
7-NI-treated animals displayed substantially greater aggression than littermates treated with vehicle control (Fig. 1) the number of attacks by 7-NI-treated animals quadrupled, while the number of bites almost tripled, with a lesser increase in the number of pursuits. The duration of each aggressive en-counter was also substantially increased in the 7-NI-treated animals as was the proportion of encounters that involved aggression.
Blinded observation of interactions between vehicle-and 7-NI-treated animals confirmed the quantified behavior. When placed together, the 7-NI-treated animals rapidly initiated aggressive behavior that they maintained even when the resident mouse adopted a submissive posture. It was necessary to separate the animals within 5 min to prevent serious injury. This behavior closely resembles that of nNOS-animals previously examined in our laboratory (4) .
By contrast, 3-I-treated animals displayed diminished aggressive behavior. The mean number of aggressive episodes was reduced by more than 75% in 3-I-treated animals. The extent of diminished aggressive encounters was similar for attacks, bites, and pursuits. There was a similar diminution of duration of such encounters as well as a decrease in the proportion of attacks initiated by the resident mice.
We also evaluated aggressive behavior between drug-treated animals in groups. We placed groups of four vehicle-treated, 7-NI-, or 3-Itreated males together in an aquarium. In this model the duration and number of aggressive encounters almost doubled following 7-NI treatment (Fig. 2) . There was some nonsignificant decrease in numbers of aggressive encounters in 3-I-treated mice.
Alterations in apparent aggressive behavior might derive from abnormalities in overall locomotor activity. We quantified overall locomotor activity and observed no differences between 7-NI-, 3-I-, and vehicle-treated animals. We (Fig. 3) . Thus, the treatment regiment for 7-NI that we have employed virtually abolishes the formation of citrulline and, presumably, NO in neurons. We also examined nNOS staining in all animals and observed no drug-induced alteration in the brain (Fig. 3) .
DISCUSSION
In the present study we of NOS (endothelial, inducible, neuronal) in vitro, 7-NI displays similar potency in inhibiting all three (13) . However, in intact animals, 7-NI inhibits NOS activity in brain extracts while not elevating blood pressure (9). It is not clear whether 7-NI fails to inhibit eNOS in intact animals because of lack of bioavailability in blood vessels or whether it inhibits eNOS but elicits some other effect that prevents hypertension. Conceivably, monitoring citrulline staining in blood vessels can clarify this issue.
Immunohistochemical staining revealed virtual abolition of neuronal citrulline in all brain regions examined following 7-NI treatment. This indicates that assays of NOS activity in brain homogenates underestimate the extent of inhibition. Indeed, chronic treatment with L-nitroarginine produces a similar outcome with -70% inhibition in brain homogenates but virtual abolishment of neuronal citrulline staining (10, 14, 15) . Presumably, when tissue is homogenized for enzyme assays, the drug is sufficiently diluted to diminish the extent of enzyme inhibition. Also, NOS activity in brain homogenates may be higher than in intact brain tissue because of dilution of endogenous inhibitors such as protein inhibitor of NOS (PIN) (16) .
In assays of brain homogenates, a single dose of 7-NI inhibits NOS activity by 75-80%. However, NOS activity recovers substantially in less than 1 hr (12) . With the protocol employed in this study, utilizing multiple injections of 7-NI, brain NOS activity also increases after the last administration of the drug, although not as rapidly as after a single dose of 7 (18, 19) . Studies are currently underway backcrossing animals to a pure C57BL/6J background so that nNOSanimals will represent a pure C57BL/6J strain (T. M. Dawson, in preparation).
Genes that are "knocked out" have been deleted from the earliest embryonic stages, presumably leading to multiple compensatory alterations. Aberrant behavior could stem from these alterations rather than resulting directly from loss of the targeted gene. Enzyme inhibitors that inhibit specific isoforms of NOS are useful in addressing this issue.
Because excess production of NO may be pathophysiologic in conditions such as ischemic stroke (20, 21) , there has been a substantial effort to develop nNOS inhibitors. Our findings of dramatic augmentations of aggressive behavior soon after the administration of an nNOS inhibitor raise concerns about adverse sequelae of such agents.
